Halfpoint Images/Getty Images
Metformin, the world’s most widely prescribed medication for type‑2 diabetes, has recently been highlighted as a promising candidate for slowing brain aging. A cascade of research—from a 2017 Australian meta‑analysis to a 2024 study by the Chinese Academy of Sciences in Beijing, and most recently a 2025 paper from Baylor College of Medicine—has begun to illuminate how this classic drug may extend healthy cognitive lifespan.
First introduced in the 1950s under the brand names Glucophage and Riomet, metformin was approved by regulatory agencies largely because its adverse effects are uncommon and typically mild. Over time, clinicians discovered that beyond glucose control, the drug reduces cardiovascular risk and can promote modest weight loss. These ancillary benefits earned it the nickname “wonder drug” among specialists.
Today, metformin is routinely prescribed off‑label for conditions such as gestational diabetes, prediabetes, polycystic ovary syndrome, and to counteract the weight‑gain side effects of certain antipsychotic medications. While it is not yet an official anti‑aging therapy, emerging evidence suggests it could be a critical step toward enhancing longevity.
For years, clinicians understood that metformin was effective, but the underlying mechanism remained elusive. The 2025 Baylor study shed light on this mystery by identifying a specific neural pathway that the drug targets.
Neurons in the hypothalamus contain a GTPase enzyme known as neuronal Rap1, which regulates energy balance, leptin signaling, and glucose production. Metformin inhibits Rap1 activity within the hypothalamic region, thereby lowering blood sugar levels without the need for insulin. The research team pinpointed SF1 neurons—cells that safeguard against metabolic dysregulation—as key mediators of this effect.
“Metformin’s ability to dampen brain Rap1 signaling may also underpin its anti‑aging properties,” said Dr. Makoto Fukuda, a co‑author of the study. “Further investigations are needed to confirm this link.”
Until more definitive studies emerge, patients should continue to avoid lifestyle habits known to accelerate aging while exploring the potential benefits of metformin under medical guidance.
